CMG Pharmaceutical Co. Ltd
CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic colla… Read more
CMG Pharmaceutical Co. Ltd (058820) - Total Assets
Latest total assets as of September 2025: ₩307.70 Billion KRW
Based on the latest financial reports, CMG Pharmaceutical Co. Ltd (058820) holds total assets worth ₩307.70 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CMG Pharmaceutical Co. Ltd - Total Assets Trend (2011–2024)
This chart illustrates how CMG Pharmaceutical Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
CMG Pharmaceutical Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
CMG Pharmaceutical Co. Ltd's total assets of ₩307.70 Billion consist of 44.4% current assets and 55.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0.9% |
| Accounts Receivable | ₩32.41 Billion | 10.7% |
| Inventory | ₩23.79 Billion | 7.8% |
| Property, Plant & Equipment | ₩77.98 Billion | 25.7% |
| Intangible Assets | ₩19.28 Billion | 6.4% |
| Goodwill | ₩2.27 Billion | 0.8% |
Asset Composition Trend (2011–2024)
This chart illustrates how CMG Pharmaceutical Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CMG Pharmaceutical Co. Ltd's current assets represent 44.4% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 0.9% of total assets in 2024, down from 4.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 5.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 25.7% of total assets.
CMG Pharmaceutical Co. Ltd Competitors by Total Assets
Key competitors of CMG Pharmaceutical Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
CMG Pharmaceutical Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - CMG Pharmaceutical Co. Ltd generates 0.33x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, CMG Pharmaceutical Co. Ltd generates $ 0.89 in net profit.
CMG Pharmaceutical Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.08 | 1.60 | 10.70 |
| Quick Ratio | 0.75 | 1.37 | 9.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩7.57 Billion | ₩ 49.93 Billion | ₩ 132.33 Billion |
CMG Pharmaceutical Co. Ltd - Advanced Valuation Insights
This section examines the relationship between CMG Pharmaceutical Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.30 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 25.3% |
| Total Assets | ₩303.44 Billion |
| Market Capitalization | $127.53 Million USD |
Valuation Analysis
Below Book Valuation: The market values CMG Pharmaceutical Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: CMG Pharmaceutical Co. Ltd's assets grew by 25.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CMG Pharmaceutical Co. Ltd (2011–2024)
The table below shows the annual total assets of CMG Pharmaceutical Co. Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩303.44 Billion | +25.34% |
| 2023-12-31 | ₩242.10 Billion | +13.52% |
| 2022-12-31 | ₩213.26 Billion | +7.07% |
| 2021-12-31 | ₩199.17 Billion | +1.95% |
| 2020-12-31 | ₩195.36 Billion | +1.62% |
| 2019-12-31 | ₩192.24 Billion | +68.07% |
| 2018-12-31 | ₩114.38 Billion | +4.39% |
| 2017-12-31 | ₩109.57 Billion | -1.27% |
| 2016-12-31 | ₩110.98 Billion | +96.31% |
| 2015-12-31 | ₩56.53 Billion | -2.64% |
| 2014-12-31 | ₩58.07 Billion | +3.86% |
| 2013-12-31 | ₩55.91 Billion | -2.09% |
| 2012-12-31 | ₩57.11 Billion | +109.15% |
| 2011-12-31 | ₩27.31 Billion | -- |